Nitric oxide synthase inhibitors in cardiogenic shock: present and future

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Cardiogenic shock (CS) following myocardial infarction has a high fatality rate (40-50%).
• Myocardial dysfunction in CS may involve excessive nitric oxide (NO) production and inflammation.
• CS survivors often experience good long-term quality of life.

Purpose of the Study:

• To review available data on nitric oxide synthase (NOS) inhibitors for treating CS.
• To evaluate the efficacy and safety of therapies targeting NO overproduction in human CS patients.

Main Methods:

• Review of mammalian research, including inducible-NOS-knockout mice studies.
• Analysis of human randomized clinical trials, focusing on the TRIUMPH trial of L-NMMA (Tilarginine Acetate).

Main Results:

• Mammalian studies suggest NO overproduction contributes to CS injury.
• Human trials indicate NOS inhibitors are safe but lack clinical efficacy.
• The TRIUMPH trial found no benefit from L-NMMA infusion in CS patients.

Conclusions:

• Current human trials show a lack of efficacy for NOS inhibitors in CS.
• Optimal timing, dosing, and duration of NOS inhibitors require further investigation.
• Therapeutic strategies targeting NO overproduction in CS warrant continued research.